HIGHLIGHTS
- who: Glen Wunderlich from the Ridgefield, CT, USA Department of Psychiatry, Medical Faculty, University Hospital Cologne have published the research work: Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimeru2019s dementia: a randomized controlled trial, in the Journal: (JOURNAL) of August/18,/2016
- what: In 2018, the NIA-AA changed their diagnostic criteria of AD for research purposes from a clinical to biological definition, with biomarker and neuropathological findings now forming the basis of these criteria . Previous reports indicate that approximately 40-80% of patients with AD carry at least one copy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.